Literature DB >> 12354845

Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

M A Pfaller1, D J Diekema.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12354845      PMCID： PMC130894          DOI： 10.1128/JCM.40.10.3551-3557.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  59 in total

Review 1.  Antimicrobial resistance surveillance: methods will depend on objectives.

Authors:  Deirdre Lewis
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

2.  Epidemiology of candidemia.

Authors:  P Sandven
Journal:  Rev Iberoam Micol       Date:  2000-09       Impact factor: 1.044

3.  High rate of non-albicans candidemia in Brazilian tertiary care hospitals.

Authors:  A L Colombo; M Nucci; R Salomão; M L Branchini; R Richtmann; A Derossi; S B Wey
Journal:  Diagn Microbiol Infect Dis       Date:  1999-08       Impact factor: 2.803

4.  Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

Authors:  M A Pfaller; D J Diekema; R N Jones; S A Messer; R J Hollis
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

5.  Epidemiology of nosocomial fungal infections.

Authors:  S K Fridkin; W R Jarvis
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

6.  Frequency, intensity, species, and strains of oral Candida vary as a function of host age.

Authors:  C L Kleinegger; S R Lockhart; K Vargas; D R Soll
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

7.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

8.  International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

Authors:  M A Pfaller; R N Jones; G V Doern; A C Fluit; J Verhoef; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1999-09       Impact factor: 2.803

9.  Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection.

Authors:  R N Jones
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

Review 10.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132
View more
  77 in total

1.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  Drug resistance is not directly affected by mating type locus zygosity in Candida albicans.

Authors:  Claude Pujol; Shawn A Messer; Michael Pfaller; David R Soll
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

4.  Risk factors for candida infection of the genital tract in the tropics.

Authors:  Na Dou; Weiping Li; Enfeng Zhao; Chan Wang; Zhaozhao Xiao; Honghui Zhou
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

5.  Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.

Authors:  Ingi Lee; Neil O Fishman; Theoklis E Zaoutis; Knashawn H Morales; Mark G Weiner; Marie Synnestvedt; Irving Nachamkin; Ebbing Lautenbach
Journal:  Arch Intern Med       Date:  2009-02-23

Review 6.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2006-11-01       Impact factor: 5.948

8.  Differentiation between atypical isolates of Candida lusitaniae and Candida pulcherrima by determination of mating type.

Authors:  Thierry Noël; Anne Favel; Annie Michel-Nguyen; Abdelhak Goumar; Karim Fallague; Christiane Chastin; Florence Leclerc; Jean Villard
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

10.  Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.

Authors:  D L Horn; L Ostrosky-Zeichner; M I Morris; A J Ullmann; C Wu; D N Buell; L L Kovanda; O A Cornely
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-15       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.